Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 13;24(7):199.
doi: 10.31083/j.rcm2407199. eCollection 2023 Jul.

The Functional Erythropoetin rs1617640 Gene Polymorphism does not Affect Life Expectancy of Patients with Peripheral Arterial Disease

Wilfried Renner  1 , Uwe Langsenlehner  2 , Tanja Langsenlehner  3
Affiliations

The Functional Erythropoetin rs1617640 Gene Polymorphism does not Affect Life Expectancy of Patients with Peripheral Arterial Disease

Wilfried Renner et al. Rev Cardiovasc Med. .

Abstract

Background: A common functional variant (c.-1306A > C, rs1617640) in the gene encoding erythropoietin (EPO) has been linked to expression of erythropoietin and markers of erythropoiesis. Aim of the current study was the analysis of the role of this polymorphism for long term survival of patients with peripheral arterial disease (PAD).

Methods: EPO genotypes as well as biomarkers for erythropoiesis were analyzed in a cohort of 946 patients with PAD. Survival follow-up was performed 20 years af-ter recruitment of patients.

Results: Twenty years after recruitment, 752 (79.5%) patients were dead, 103 (10.9%) were still alive, and 91 (9.6%) were lost-to-follow up. In a Cox regression analysis including smoking habit, sex, type-2 diabetes, hypercholesterolemia and arterial hypertension, EPO genotypes were not associated with overall survival (Hazard ratio 0.63; 95% confidence interval 0.88-1.08, p = 0.63).

Conclusions: The functional EPO rs1617640 gene polymorphism, irrespective of its association with markers of erythropoiesis, does not affect survival of PAD patients.

Keywords: epidemiology; erythropoietin; genetics; peripheral artery disease; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Overall survival of peripheral arterial disease (PAD) patients. Lines are separate for EPO genotypes AA (solid line), AC (short dashes) and CC (long dashes). EPO, erythropoietin.
See this image and copyright information in PMC

References

    1. Haugen S, Casserly IP, Regensteiner JG, Hiatt WR. Risk assessment in the patient with established peripheral arterial disease. Vascular Medicine . 2007;12:343–350. - PubMed
    1. Minar E. Peripheral arterial occlusive disease. VASA. Zeitschrift Fur Gefasskrankheiten . 2007;36:155–164. - PubMed
    1. Kullo IJ, Turner ST, Kardia SLR, Mosley TH, Jr, Boerwinkle E, de Andrade M. A genome-wide linkage scan for ankle-brachial index in African American and non-Hispanic white subjects participating in the GENOA study. Atherosclerosis . 2006;187:433–438. - PubMed
    1. Murabito JM, Guo CY, Fox CS, D’Agostino RB. Heritability of the ankle-brachial index: the Framingham Offspring study. American Journal of Epidemiology . 2006;164:963–968. - PubMed
    1. Kullo IJ, Leeper NJ. The genetic basis of peripheral arterial disease: current knowledge, challenges, and future directions. Circulation Research . 2015;116:1551–1560. - PMC - PubMed

LinkOut - more resources